AbbVie hep C combo fast-tracked in U.S. and EU; Merck's Gardasil wins new indication in Europe;

> AbbVie's ($ABBV) all-oral hep C combo has won expedited assessment in both the U.S. and the EU. Report | Article

> Europe has approved Merck's ($MRK) Gardasil vaccine to prevent anal cancer. Report

> Bristol-Myers Squibb's ($BMY) "The Pink Drive" campaign took bronze at the Goafest's Abby awards. Story

> Takeda and Affymax ($AFFY) have terminated their collaboration and license agreement on anemia drug Omontys and will withdraw their NDA. More (sub. req.)

> Roche's ($RHHBY) Gazyvaro has won Swiss approval for the therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). Release

> U.K. cost watchdog NICE has given its recommendation to Sucampo Pharmaceuticals' constipation med, Amitiza. Release

> Boehringer Ingelheim has earned The Information Standard certification, commissioned by England's National Health Service, for the quality of its healthcare information. Report

And Finally... U.S. submission stumbled at the Lions Health Festival. More

Suggested Articles

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

A lawsuit says J&J helped doctors set up high-volume "infusion suites" and offered other services as kickbacks to amp up Remicade and Simponi…

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.